Liang-zhi Xie

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM SCT800 is a new third-generation recombinant FVIII agent that is undergoing promising preclinical study. This study aimed to investigate the pharmacokinetic and pharmacodynamic profiles of SCT800 in hemophilia A mice. METHODS After hemophilia A mice were intravenously injected with single dose of SCT800 (80, 180, and 280 IU/kg) or the commercially(More)
  • 1